The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination
Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study
Objective: To examine whether the response to an inhaled levodopa formulation (CVT-301; at 35 and 50 mg per dose) is dependent on baseline patient characteristics.…Characterization of burning mouth syndrome in patients with Parkinson’s disease
Objective: To determine the prevalence and characteristics of burning mouth syndrome (BMS) in a Parkinson's disease (PD) population through a self-administered survey. Background: The majority…Intrastriatal injection of ionomycin profoundly changes motor response to L-DOPA and its underlying molecular mechanisms
Objective: We investigated whether intrastriatal injection of ionomycin to hemiParkinsonian rats produced changes in L-DOPA responses including LID and analyzed the effects of ionomycin on…Prevalence of orthostatic hypotension after a low subacute levodopa dose in patients with parkinsonism
Objective: To evaluate the prevalence of orthostatic hypotension (OH) after a low subacute levodopa (LD) dose in patients with diagnosis of Parkinson's disease (PD) or…Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey
Objective: To assess socio-demographic and disease specific data in patients with Parkinson's disease (PD) before and one year after therapy escalation with subcutaneous apomorphine (APO),…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry
Objective: To evaluate the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the US as carbidopa-levodopa enteral suspension) on non-motor symptoms (NMS), quality…Preliminary results of a cross-linguistic comparison on dysarthria in Parkinson’s disease
Objective: To evaluate the effects of language, disease duration, and medication on acoustic and prosodic parameters in the speech of Parkinson's disease (PD) patients. Background:…MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum
Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 57
- Next Page »